Major Hypertension Cardiovascular Prevention Trials: Event Reduction
____________
1. Prevention of stroke by antihypertensive drug treatment in older
persons with isolated systolic hypertension. Final results of the Systolic
Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research
Group. JAMA 1991; 265:3255.
2. MRC trial of treatment of mild hypertension: principal results. Medical
Research Council Working Party. Br Med J (Clin Res Ed) 1985; 291:97.
3. Dahlöf, B, Lindholm, LH, Hansson, L, et al. Morbidity and mortality
in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension).
Lancet 1991; 338:1281.
4. Staessen JA; Fagard R; Thijs L; Celis H; Arabidze GG; Birkenhager
WH; Bulpitt CJ; de Leeuw PW; Dollery CT; Fletcher AE; Forette F; Leonetti
G; Nachev C; O'Brien ET; Rosenfeld J; Rodicio JL; Tuomilehto J; Zanchetti
A. Randomised double-blind comparison of placebo and active treatment
for older patients with isolated systolic hypertension. The Systolic
Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997350(9080):757-64.
5. Hansson, L, Zanchetti, A, Carruthers, SG, et al. Effects of intensive
blood-pressure lowering and low-dose aspirin in patients with hypertension:
Principal results of the Hypertension Optimal Treatment (HOT) randomised
trial. Lancet 1998; 351:1755.
6. Hansson, L, Lindholm, LH, Niskanen, L, et al, for the Captopril Prevention
Project (CAPPP) study group. Effect of angiotensin-converting-enzyme
inhibition compared with conventional therapy on cardiovascular morbidity
and mortality in hypertension: the Captopril Prevention Project (CAPPP)
randomised trial. Lancet 1999; 353:611.
7. Hansson, L, Lindholm, LH, Ekbom, T, et al. Randomised trial of old
and new antihypertensive drugs in elderly patients: cardiovascular mortality
and morbidity the Swedish Trial in Old Patients with Hypertension-2 study
[see comments]. Lancet 1999; 354:1751.
8. Hansson, L, Hedner, T, Lung-Johansen, P, et al, for the NORDIL Study
Group. Randomised trial of effects of calcium antagonists compared with
diuretics and beta-blockers on cardiovascular morbidity and mortality
in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359.
9. Brown, MJ, Palmer, CR, Castaigne, A, et al. Morbidity and mortality
in patients randomised to double-blind treatment with a long-acting calcium-channel
blocker or diuretic in the International Nifedipine GITS study: Intervention
as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366.
10. Randomised trial of a perindopril-based blood-pressure-lowering regimen
among 6105 individuals with previous stroke or transient ischaemic attack.
PROGRESS Collaborative Group. Lancet 2001; 358:1033.
11. Dahlof, B, Devereux, RB, Kjeldsen, SE, et al. Cardiovascular morbidity
and mortality in the Losartan Intervention for Endpoint reduction in
hypertension study (LIFE): a randomised trial against atenolol. Lancet
2002; 359:995.
12. Hansson L, Lithell H, Skoog I, Baro F, Bánki CM, Breteler
M et al .Study on COgnition and Prognosis in the Eldery (SCOPE). Blood
Press 1999;8:177-83.
13. Lithell H, Hansson L, Skoog I , Elmfeldt D, Hofman A, Olofsson B,
Trenkwalder P, Zanchetti A, for the SCOPE Study Group. The Study on Cognition
and Prognosis in the Elderly (SCOPE): principal results of a randomized
double-blind intervention trial. J.of Hypertension 2003; 21(5):875-886.
14. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman
WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil
S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM. Rationale
and design for the Antihypertensive and Lipid Lowering treatment to prevent
Heart Attack Trial (ALLHAT).Am J Hypertens 1996;9:342-60.
15. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative
Research Group. Angiotensin-Converting Enzyme Inhibitor or Calcium Channel
Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment
to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
16. Wing LMH, Reid CM, Ryan MB, Beilin LJ, Brown MA, Jennings GLR, Johnston
CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ for the Second
Australian National Blood Pressure Study Group. A Comparison of Outcomes
with Angiotensin-Converting–Enzyme Inhibitors and Diuretics for
Hypertension in the Elderly NEJM 2003;348(7):583-592.
17.Julius S, Kjeldsen SE, Brunner HR, et al for the VALUE Trial Group:Outcomes in hypertensive patients at high cardiovascular risk treatedwith regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363(9426):2022-31.
18. Poole-Wilson PA, Lubsen J, Kirwan BA, et al for the A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): Randomised controlled trial. Lancet 2004;364(9437):849-57.
19.Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al for the INVEST Investigators: A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA 2003; 290(21):2805-16.
